e-learning
resources
Breathe
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
Anna C. Murphy, Claire Boddy, Peter Bradding
Source:
Breathe, 17 (2) 210024; 10.1183/20734735.0024-2021
Journal Issue:
June
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Anna C. Murphy, Claire Boddy, Peter Bradding. Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment. Breathe, 17 (2) 210024; 10.1183/20734735.0024-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Con: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
Source: Breathe, 17 (2) 210049; 10.1183/20734735.0049-2021
Year: 2021
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Combination therapy versus separate therapy in real-life primary care asthma patients
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
Two therapy option in patients with uncontrolled asthma
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials
Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019
Year: 2019
A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study
Source: International Congress 2016 – Kaleidoscope of respiratory nursing
Year: 2016
Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses
Source: International Congress 2017 – COPD management
Year: 2017
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Life-sustaining treatment preferences of patients with severe COPD
Source: Annual Congress 2010 - Pulmonary rehabilitation and chronic care: new developments in interventions, assessment and care
Year: 2010
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
The parameters that may affect inhalation therapy success in elderly COPD and asthma patients
Source: International Congress 2015 – Co-existing diseases and asthma
Year: 2015
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Identifying patients with severe asthma that will be benefit from biological therapy
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020
Macrolide therapy in asthma: limited treatment, long-term improvement
Source: Eur Respir J 2009; 33: 1239
Year: 2009
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study
Source: International Congress 2017 – Management of COPD
Year: 2017
Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients
Source: International Congress 2019 – Inhalers: adherence and preference
Year: 2019
Suboptimal asthma control in patients receiving long-term maintenance therapy
Source: Annual Congress 2006 - The challenges of managing asthma in primary care
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept